By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced




Founder: Joshua Boger

CEO: Jeffrey Leiden

CMO (Medical): Jeffrey Chodakewitz

CFO: Ian Smith

CSO (Scientific): David Altshuler


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
2 Views On Vertex (VRTX) Stock: Short Term Vs. Long Term 9/12/2017 7:53:58 AM
Vertex (VRTX)’s Terminated Phase II CF Trial Was Planned 9/12/2017 6:25:43 AM
Vertex (VRTX) Poaches New CFO From Ironwood (IRWD) 9/6/2017 6:40:16 AM
Vertex (VRTX) Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA 8/24/2017 11:05:23 AM
Vertex (VRTX) May Be Turning Some Major Corners 8/14/2017 6:12:32 AM
For Vertex (VRTX), Can One Billion-Dollar Breakthrough Beget Another? 8/9/2017 6:01:21 AM
Vertex (VRTX) Release: FDA Approves KALYDECO (Ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations 8/1/2017 6:21:14 AM
Vertex (VRTX) Reports Second-Quarter 2017 Financial Results 7/27/2017 7:54:32 AM
Vertex (VRTX) And Concert Pharma (CNCE) Complete Asset Purchase Agreement For CTP-656 7/26/2017 7:29:06 AM
Concert Pharma (CNCE) Announces Termination Of The HSR Act Waiting Period For CTP-656 Asset Purchase Agreement With Vertex (VRTX) 7/24/2017 7:52:19 AM